You are here:

tiotropium/olodaterol (Spiolto Respimat)

Advice

following an abbreviated submission

tiotropium/olodaterol (Spiolto® Respimat®) is accepted for use within NHS Scotland.

Indication under review: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Spiolto® Respimat® should be used in patients for whom tiotropium and olodaterol are appropriate choices of antimuscarinic and long-acting beta2-agonist respectively.

Tiotropium/olodaterol (Spiolto® Respimat®) is available at a lower cost than the individual inhalers given separately.
 

Drug Details

Drug Name: tiotropium/olodaterol (Spiolto Respimat)
SMC Drug ID: 1099/15
Manufacturer: Boehringer Ingelheim Ltd
Indication: Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 9 November 2015

Back